


Cite this: *RSC Adv.*, 2020, 10, 37134

# Multicomponent crystals of anti-tuberculosis drugs: a mini-review†

Eustina Batisai 

Tuberculosis (TB) is the leading cause of death from a single infectious agent globally. Some of the early research on TB treatment indicated drug resistance as one of the key challenges in fighting this disease. The discovery that administering two or more drugs simultaneously could lead to much more effective treatment, with reduced drug resistance and shorter periods of chemotherapy, was, therefore, a very significant breakthrough in TB drug research. Pursuant to this discovery, the World Health Organisation (WHO) recommended TB treatment employing fixed-dose combinations (FDCs) containing first line anti-TB drugs; rifampicin, isoniazid, pyrazinamide, streptomycin and ethambutol. Regardless, certain challenges associated with FDCs remain and these include chemical instability and reduced bioavailability of rifampicin. Therefore, some research effort has been directed towards finding ways to deal with these challenges. One such effort involves the use of pharmaceutical co-crystals of the active pharmaceutical ingredients. Consequently, several pharmaceutical co-crystals of isoniazid and pyrazinamide have been reported. This paper aims at reviewing the multicomponent crystal structures of two first-line anti-TB drugs; isoniazid and pyrazinamide. The review will first set out a brief history of the disease, milestones in TB chemotherapy and the challenges associated with current treatment regimens. This will then be followed by a brief introduction to pharmaceutical co-crystals and how they can improve the physical and chemical properties of the active pharmaceutical ingredients. Secondly, multicomponent crystals of the two active pharmaceutical ingredients will be analysed by manual inspection for common supramolecular synthons between the drug molecules as well as between drug molecules and co-formers. Lastly; stability, solubility and dissolution experiments carried out on the pharmaceutical co-crystals of pyrazinamide and isoniazid will be analysed to gain insights into progress made with regards to improving stability and solubility of the active pharmaceutical ingredients.

Received 26th July 2020  
Accepted 29th September 2020

DOI: 10.1039/d0ra06478e

rsc.li/rsc-advances

## 1. Introduction

Tuberculosis (TB) is an infectious disease caused by the bacillus *Mycobacterium tuberculosis*. Even though the bacterium was discovered in March 1882 by Robert Koch, studies have only recently revealed that the bacterium may, in fact, have infected humans for thousands of years before its discovery.<sup>1</sup> TB is currently one of the leading causes of death globally, and the World Health Organisation (WHO) estimates 10.0 million infections and 1.3 million deaths worldwide in 2018.<sup>2</sup> It is, therefore, a global epidemic of significant concern. The prevention of new infections and their progression to TB disease is at the core of the fight against TB. This is currently only possible through the vaccination of children using the Bacille Calmette-Guérin (BCG) vaccine. Fully progressed TB, on the other hand, can be treated using a fixed-dose combination (FDC) containing four first line TB drugs: rifampicin, isoniazid, pyrazinamide and ethambutol.<sup>3</sup> Such treatment entails a six-to-eight-month-long FDC course at an approximate cost of USD40 per person and has an 85% cure rate. Regardless, the history of TB treatment is plagued with various challenges, in

Department of Chemistry, University of Venda, P. Bag X5050, Thohoyandou, 0920, South Africa. E-mail: Eustina.Batisai@univen.ac.za

† Electronic supplementary information (ESI) available. See DOI: 10.1039/d0ra06478e



*Eustina Batisai obtained B.Sc. Honors, M.Sc. and PhD Chemistry degrees from Stellenbosch University. She was then awarded postdoctoral fellowships at the Cape Peninsula University of Technology and University of Cape Town. She is currently a Senior Lecturer at the University of Venda. Her research interests include structure-property relationships in co-crystals and in metal organic frameworks.*



particular, emergent drug resistance towards the first line drugs rifampicin and isoniazid.<sup>4</sup> Treatment of multi-drug resistant TB is much more expensive (1000 USD per person) and it involves the use of toxic drugs and a longer treatment period. Even then, such treatment is successful in only 55% of reported cases.<sup>3</sup>

A survey of the history of the development of TB treatment drugs reveals that, despite many drug candidates showing initial promise, the emergence of drug resistance in the bacteria has posed one of the biggest challenges. The earliest TB treatment attempts employed the antibiotic streptomycin, which was discovered by Schatz, Bugie and Waksman in 1944.<sup>5</sup> In monotherapy trials conducted by the British Medical Research Council (BMRC),<sup>6</sup> for the treatment of pulmonary TB from 1946 onwards, a streptomycin-resistant strain was isolated in 85% of the patients under treatment within two months of commencement.<sup>6</sup> It quickly became evident that single-drug therapy would most likely result in the emergence of drug resistance. A breakthrough in TB drug research came in 1948 when it was shown that combined therapy of streptomycin and *para*-aminosalicylic acid (PAS) led to improved protection against the emergence of resistance.<sup>7</sup> *Para*-aminosalicylic acid's antibacterial activity had first been reported in 1946.<sup>8</sup> Another milestone followed in 1952<sup>9</sup> when isoniazid, a drug first synthesized in 1912,<sup>10</sup> showed anti-TB activity. Subsequent studies showed that even though isoniazid monotherapy is effective in pulmonary TB treatment, it is not more effective than combined therapy of streptomycin plus PAS.<sup>11</sup> It was now becoming clear that mono-therapeutic drugs were much more susceptible to the emergence of drug resistance, TB drug development increasingly focused on combination therapy and the development of FDCs. The challenge lay in finding both the suitable candidate drugs and the correct combination. During the 1952 to 1955 period, combination therapy utilizing PAS plus isoniazid and, streptomycin plus isoniazid were explored.<sup>12</sup> These studies led to the triple therapy lasting up to twenty-four months which involved the use of all three drugs for TB treatment for almost fifteen (15) years.<sup>13,14</sup> A very important breakthrough came in the 1970s when it was discovered that the addition of rifampicin and pyrazinamide to the regimens shortened chemotherapy to six months.<sup>15,16</sup> The potential efficacy of pyrazinamide<sup>17</sup> and rifampicin<sup>18</sup> had been reported over the course of TB drug research. A fourth drug usually included in combination therapy in case there is unknown resistance to isoniazid is ethambutol whose anti TB activity was first realized in 1961.<sup>19</sup>

Despite the progress, TB drug resistance remains a global problem. Therefore, current approaches in TB drug development that seek to address this problem include the development of new drugs, as well as re-formulations of existing drugs. According to a recent WHO report, there are twenty (20) new TB drugs as well as combination regimens currently being tested in clinical trials.<sup>3</sup> The development of FDCs represents significant progress in combating drug resistance. However, FDCs are also plagued by their challenges which include chemical instability as well as the reduced bioavailability of rifampicin. The reduction in the bioavailability of rifampicin has been attributed to drug–drug interactions between rifampicin and isoniazid.

Singh *et al.* postulated that under acidic conditions rifampicin is first hydrolysed to 3-formylrifamycin which then reacts with isoniazid to yield isonicotinyl hydrazone (HYD). The isonicotinyl hydrazone, which is unstable under acidic condition is then converted back to isoniazid and 3-formylrifamycin. This results in the recovery of isoniazid but not rifampicin.<sup>20–22</sup> The chemical instability of the FDCs arises due to the direct interaction of the imine group on the rifampicin and the amine group of the isoniazid. This results in the formation of isonicotinyl hydrazone. The other reason is due to the moisture gain by ethambutol hydrochloride which creates a hydrolytic environment. This accelerates the reaction between isoniazid and rifampicin.<sup>20</sup>

There is a lot of ongoing research focused on combating the low-bioavailability of rifampicin and the chemical instability of FDCs. Crystal engineering, defined as the study and utilization of intermolecular interactions in designing new solids with specific desired properties,<sup>23</sup> is one of the most promising techniques employed to solve these problems faced with FDCs. Co-crystallization is a subfield of crystal engineering which involves crystallizing an active pharmaceutical ingredient with a pharmaceutically acceptable compound known as a co-former. The resulting compound, known as a pharmaceutical co-crystal or salt, usually exhibits improved physical and chemical properties compared to those of the active pharmaceutical ingredient.<sup>24–26</sup>

Hydrogen bonding, ionic interactions,  $\pi$ – $\pi$  stacking interactions, van der Waals interactions and halogen bonding are some of the interactions utilized in co-crystal formation.

Different methods are employed in the synthesis of co-crystals. These may be broadly classified based on whether a solvent is involved in the crystallization process. Solution-based methods include solvent evaporation, reaction co-crystallization, cooling co-crystallization, anti-solvent addition co-crystallization, slurry co-crystallization and ultrasound assisted co-crystallization. Solvent-free methods, on the other hand, include neat grinding, liquid assisted grinding, polymer assisted grinding, hot melt extrusion and matrix-assisted co-crystallization.<sup>27</sup> A more thorough discussion of these as well as other related techniques; their advantages and disadvantages can be found in the review by Rodrigues and co-workers.<sup>27</sup> Studies have shown that the solvent polarity plays a very important role in the self-assembly process during co-crystal formation in both solvent-based techniques as well as solvent-less techniques.<sup>28,29</sup> Co-crystals can be characterised using crystallographic techniques (single crystal X-ray diffraction and powder X-ray diffraction), spectroscopy (solid state nuclear magnetic resonance and NMR crystallography and, vibrational spectroscopy) and thermal analysis (differential scanning calorimetry, thermogravimetric analysis, hot stage microscopy).<sup>30</sup> For a more comprehensive discussion of these techniques the reader is referred to a review by Pindelska and co-workers.<sup>30</sup>

A significant amount of work that addresses how co-crystallization has improved some properties of anti-TB drugs has been published. This paper reviews the pharmaceutical co-crystals of pyrazinamide and isoniazid, published to date which comprise the one hundred and ten (110) multicomponent



crystals of isoniazid and forty-nine (49) co-crystals of pyrazinamide deposited in the Cambridge Structural Database (CSD) (Version 5.5, March 2020).<sup>31</sup> Data on the solubility, stability and dissolution rates for these co-crystals will be analysed to evaluate the progress made in improving the stability and solubility of the drugs. In addition, the presence of common supramolecular synthons between drug molecules, as well as between drug molecules and co-formers will be examined. Understanding the nature of these interactions is crucial for the further development of pharmaceutical co-crystals of these drugs.

## 2. Common synthons in multicomponent crystals of isoniazid and pyrazinamide

Isoniazid (INH) and pyrazinamide (PYZ) (Fig. 1) are excellent supramolecular reagents possessing both hydrogen bond acceptors and donors. The pyridyl functionality in INH can act as a hydrogen bond acceptor, whilst the  $-\text{CO}-\text{NH}-\text{NH}_2$  functionality possesses both hydrogen bond acceptors and donors. PYZ contains the pyrazyl functionality which can act as a hydrogen bond acceptor whilst the  $-\text{CO}-\text{NH}_2$  group can act as both a hydrogen bond acceptor and a hydrogen bond donor. This presents opportunities in understanding intermolecular interactions formed with the different co-formers and, therefore, both drugs have been successfully co-crystallized with a variety of organic and inorganic compounds. This section thus analyses structures of multicomponent crystals of both drugs deposited in the CSD for common supramolecular synthons.

### 2.1. Isoniazid

A Cambridge Structural Database (CSD) (Version 5.5, March 2020) search produced one hundred and ten (110) multicomponent crystals of isoniazid. Of these, one hundred and one (101) contain organic compounds as co-formers, whilst the remaining are prepared from various inorganic acids. The multicomponent crystals were analysed by manual inspection and the most common synthons observed in the structures are shown in Fig. 2. The co-crystal formers, CCDC reference codes, common synthons and physical properties addressed for multicomponent crystals of isoniazid are given in Table S1.†

Carboxylic acid is the most commonly utilized functionality in the preparation of co-crystals of isoniazid, accounting for 86% (87 hits) of the multicomponent crystals that contain




Fig. 2 Common synthons formed by INH in the multicomponent crystals deposited in the CSD.

organic co-formers. The remaining contain macrocyclic compounds (five (5) hits) and other organic compounds (nine (9) hits). The eighty-seven (87) multicomponent crystals containing carboxylic acids comprise seventeen (17) salts and seventy (70) co-crystals. Fifty-nine (59) of the co-crystal structures display the expected pyridyl...acid heterosynthon (synthon type I) (Fig. 2). Of these fifty-nine (59), twenty-seven (27) display synthon type II. Synthon types III, IV, V and VI are observed in ten (10), eleven (11), six (6) and twenty-four (24) structures respectively (Fig. 2). Analysis of the seventeen (17) salts indicated that the pyridyl- $\text{H}^+\cdots\text{OOC}^-$  heterosynthon is utilized in 69% of the salts. The co-crystal formers, CCDC reference codes, common synthons and physical properties addressed for multicomponent crystals of isoniazid are given in Table S2.†

### 2.2. Pyrazinamide

The first co-crystal of pyrazinamide reported by Aakeröy and co-workers in 2004<sup>32</sup> was prepared from the slow evaporation of an ethanol solution of a 1 : 1 mixture of pyrazinamide and 4-nitrobenzamide. The interactions in this co-crystal were described by the authors as unpredictable because of the absence of primary interactions between pyrazinamide and the 4-nitrobenzamide molecules. Since 2004, a lot of research has been conducted in the study of co-crystals of pyrazinamide, and to date, there are forty-nine (49) multicomponent crystal structures of pyrazinamide deposited in the CSD. The most common synthons between the pyrazinamide molecules in the multicomponent crystals are presented in Fig. 3. Of the reported forty-nine (49) structures, thirty-four (34) contain carboxylic acid co-formers, thirteen (13) contain other organic compounds including drug co-formers (hydrochlorothiazide, temozolomide, theophylline and quercetin), one (1) contains an inorganic compound and one (1) is a clathrate prepared from cyclodextrin. Of the thirty-four (34) containing carboxylic acid





Fig. 1 Structures and abbreviations of isoniazid and pyrazinamide.






Fig. 3 Common synthons formed by PYZ molecules in the multi-component crystal structures of pyrazinamide deposited in the CSD.

co-formers, fifteen (15) contain the pyrazyl-N $\cdots$ HOOC hetero-synthon (synthon VII) with eleven (11) of these featuring synthon VIII. Synthon IX appears in twenty-two (22) structures, synthon X appears in eight (8) structures and synthon XI appears in six (6) structures (Fig. 3).

### 3. Multicomponent crystals of isoniazid that address the issue of stability and solubility

Isoniazid, on its own, is stable at ambient conditions (30 °C and 40% relative humidity) as well as at accelerated conditions (40 °C and 75% relative humidity). However, in FDCs, its stability is reduced due to drug–drug interactions. This section reviews the pharmaceutical co-crystals of isoniazid that sought to address the issues of stability and solubility. The equilibrium solubility values of the multicomponent crystals reviewed in this section are given in Table 1.

Diniz *et al.* crystallized isoniazid (INH) with oxalic acid (OXA), maleic acid (MAL) and methanesulfonic acid (MES).<sup>33</sup> The solubility of the resulting salts, as well as INH, were determined in water, and in pH 6.8, 4.5 and 1.2 buffers (Table 1). Except for the INH·OXA salt, the other salts generally have higher solubility in all dissolution media compared to INH. The solubility of the salts in water and pH 6.8 buffer follows the order INH·MES > INH·MAL > INH > INH·OXA while the solubility in pH 4.5 and 1.2 buffers follow the order INH·MAL > INH·MES > INH > INH·OXA.

Aitipamula and co-workers studied the stability and solubility of co-crystals of isoniazid with fumaric acid (FA), succinic acid (SA), nicotinamide (NA) and 4-hydroxybenzoic acid (HBA).<sup>34</sup> The authors also report two concomitant polymorphs of the INH·HBA hydrate, a new polymorph of INH·FA co-crystal and two ternary co-crystals; INH·NA·FA and INH·NA·SA. Form I of the INH·HBA hydrate crystallizes in the monoclinic space group

$P2_1/n$  while form II crystallizes in the monoclinic space group  $P2_1$ . Form I<sup>35</sup> and form II of INH·FA both crystallize in the monoclinic space group  $P2_1/n$ . The stability of the co-crystals was determined by performing slurry experiments at 37 °C for 24 hours, storing the co-crystals at 40 °C and 75% RH and dynamic vapour sorption (DVS) experiments. The ternary co-crystals were found to be stable while the form I of INH·HBA hydrate, as well as the anhydrous INH·HBA co-crystal,<sup>36</sup> were converted to form II INH·HBA hydrate, whereas form II of INH·FA converts to form I INH·FA upon slurrying. Stability experiments performed at accelerated conditions showed that the two ternary co-crystals, INH·FA form I and INH·HBA hydrate form II are stable up to thirteen (13) weeks while the anhydrous INH·HBA converts to form II INH·HBA hydrate within two days of storage. The solubility studies carried out on the co-crystals in the pH 7.5 buffer showed that, except in the case of the ternary co-crystal INH·NA·SA which has solubility 1.5 times higher than the INH, the solubility of the co-crystals were lower than the solubility of INH (Table 1). The high solubility of INH·NA·SA was attributed to the high solubility of the SA and NA.

Sarcevic *et al.*<sup>37</sup> prepared INH co-crystals of suberic acid (SUB), sebacic acid (SEB) benzoic acid (BA) and cinnamic acid (CIN). The stability and solubility of the resulting co-crystals as well as the previously reported co-crystals of INH and malonic (INH·MALO), succinic (INH·SUC), glutaric (INH·GLT), adipic (INH·ADI) and pimelic (INH·PIM) were investigated. Co-crystallization of isoniazid with suberic acid yielded two polymorphs crystallizing in the triclinic space group  $P1$  and monoclinic space group  $P2_1/c$ . Isoniazid and cinnamic acid also yielded two polymorphs crystallizing in the triclinic space group  $P1$  and monoclinic space group  $P2_1/c$ . The stability of INH·MALO, INH·SUC, INH·GLT, INH·ADI and INH·PIM were investigated by storing the compounds at 30 °C and 75% relative humidity for eight (8) weeks. The stability experiments indicated that the INH·MALO decomposed after four (4) weeks while the rest of the co-crystals remained intact for the entire duration of the testing period. To determine the stability of pure INH and the triclinic form of INH·CIN, the compounds were stored at 30 °C and 75% relative humidity for eleven (11) weeks. The compounds were stable over the experimental period. Stability experiments for INH·BA, INH·SEB and INH·SUB (monoclinic form) conducted at 30 °C and 75% relative humidity for 22 weeks showed that the INH·BA co-crystal decomposes after 2 weeks while the INH·SEB remained stable over the experimental period. The poor stability of the INH·BA co-crystal was attributed to the fewer hydrogen bonds between the benzoic acid and the isoniazid molecules. When determined using deionized water at  $22 \pm 1$  °C, the solubility of INH·MALO, INH·SUC, INH·GLT, INH·SUB and INH·BA were higher than the solubility of INH while the remaining were lower than that of INH (Table 1). The higher solubility values of the INH·MALO, INH·SUC, INH·GLT co-crystals were attributed to the high solubility values of the dicarboxylic acids, while the high solubility of INH·BA was attributed to its instability.

Swapna *et al.*<sup>38</sup> reported stability studies of co-crystals of INH with ferulic acid (FRA), vanillic acid (VLA), caffeic acid (CFA) and

Table 1 Equilibrium solubility values of INH and INH co-crystals determined in different media

Dissolution medium	Co-crystal	Solubility (mg mL <sup>-1</sup> )	Reference
Water	INH	137.96	33
	INH·OXA	5.43	
	INH·MAL	403.95	
pH 6.8 buffer	INH·MES	485.91	33
	INH	137.96	
	INH·OXA	8.13	
pH 4.5 buffer	INH·MAL	307.25	33
	INH·MES	322.67	
	INH	108.75	
pH 1.2 buffer	INH·OXA	8.64	33
	INH·MAL	411.7	
	INH·MES	372.14	
pH 7.5 buffer	INH	148.41	33
	INH·OXA	8.96	
	INH·MAL	422.79	
Water	INH·MES	410.82	34
	INH	183	
	INH·HBA hydrate (form II)	17.9	
Water	INH·HBA anhydrous	Converts to hydrate	37
	INH·FA (form I)	66.5	
	INH·NA·FA	131	
Water	INH·NA·SA	285	37
	INH·CIN	6.9 ± 0.5	
	INH·BA	137 ± 9	
Water	INH·MALO	375 ± 23	37
	INH·SUC	128 ± 7	
	INH·GLT	302 ± 9	
Water	INH·ADI	73 ± 2	37
	INH·PIM	83 ± 1	
	INH SUB	164 ± 4	
Water	INH·SEB	86 ± 4	37

resorcinol (RES) namely INH·FRA form I, INH·FRA form II, INH·VLA-form 1, INH·VLA form II, INH·CFA form I, INH·CFA form II, INH·CFA form III and INH·RES. Stability tests were carried out at ambient conditions (35 °C and 40% RH) as well as at accelerated conditions (40 °C, 75% RH). All the co-crystals were stable for more than twelve months at ambient conditions. At accelerated conditions, INH·RES dissociated after one month while the rest were stable for up to six months. In addition, no polymorphic transition or hydrate formation was observed for all the co-crystals. Rosa *et al.*<sup>39</sup> prepared a co-crystal of INH and resveratrol; INH·RES. The solubility was determined in the pH range 1.2 to 7.4 and it was found that INH·RES has low solubility compared to that of INH.

During treatment, TB patients may experience oxidative stress due to tissue inflammation and free radical burst from activated macrophages. These free radicals are usually treated with anti-oxidants. Therefore, there has been a few reports on the pharmaceutical co-crystals of anti-TB drugs containing anti-oxidant co-formers, these include a co-crystal of INH and *p*-coumaric acid by Ravikumar *et al.*<sup>40</sup> and co-crystals of INH and gallic acid, 3-hydroxybenzoic acid, 3,5-dihydroxybenzoic acid and 2,3-dihydroxybenzoic acid by Mashhadi *et al.*<sup>41</sup> Mashhadi *et al.* also reported a hydrate co-crystal of INH with an antioxidant and anti-bacterial protocatechuic acid.<sup>42</sup> The co-crystal was

found to be less soluble in a pH 7.4 buffer but had greater stability at 80 °C compared to INH.

#### 4. Drug–drug and drug-bridge-drug co-crystals of PYZ and INH

Drug–drug co-crystals present a new potential strategy for administering the fixed dose combinations (FDCs). This would be possible if the two drugs have complementary functional groups. Grobelny *et al.*<sup>43</sup> prepared a 1 : 1 co-crystal of INH and 4-aminosalicylic acid. The molecules in the co-crystal are joined by the COOH...N-pyridyl heterosynthon. The authors also reported a 1 : 1 monohydrate of pyrazinamide and 4-aminosalicylic acid, in which the COOH...N-pyrazyl heterosynthon also joins the two drugs.<sup>43</sup> Other drug–drug co-crystals of pyrazinamide reported in the literature include co-crystals of pyrazinamide and, temozolomide,<sup>44</sup> entacapone,<sup>45</sup> quercetin<sup>46</sup> and hydrochlorothiazide.<sup>47</sup> Drug–drug co-crystals containing isoniazid and, hydrochlorothiazide<sup>48</sup> and 5-fluorocytosine<sup>49</sup> have also been reported. In some cases, however, co-crystallizing two drugs may be challenging. One approach that has been developed for dealing with drugs that are difficult to co-crystallize has been through the formation of a drug-bridge-drug co-crystal in which two drug molecules are linked *via* a pharmaceutically



acceptable molecule. Cherukuvada and co-workers<sup>35</sup> attempted to prepare a 1 : 1 co-crystal of isoniazid and pyrazinamide, INH·PYZ *via* solution crystallization and grinding. Solution crystallization was unsuccessful, however, the grinding method yielded INH·PYZ eutectic. In addition, two ternary eutectics containing succinic acid (SA), and fumaric acid (FA) namely PYZ·SA·INH and PYZ·FA·INH were also prepared *via* grinding. Solubility studies on the three eutectics indicated that they display a superior intrinsic dissolution rate (IDR) compared to PYZ and follow the order PYZ·SA·INH > INH > PYZ·INH > PYZ·FA·INH > PYZ. Stability studies conducted at ambient conditions (15–40 °C and 30–70% RH) showed that the compounds are stable up to 1 year. Liu *et al.*<sup>50</sup> prepared ternary co-crystal containing INH and pyrazinamide (PYZ) linked by a fumaric acid bridge (PYZ·FA·INH). The solubility tests were conducted in pH 1.2, 4.0 and 6.8 buffer solutions. The results indicated that the ternary co-crystal is most soluble in pH 6.8 buffer and that the formation of a ternary co-crystal with the two drugs managed to increase the poor solubility of PYZ and reduce the solubility of INH. It is postulated that the co-crystal may be more bioavailable compared to the two drugs.

## 5. Pharmaceutical co-crystals of pyrazinamide that address the issue of solubility

The solubility values of multicomponent crystals described in this section are given in Table 2. Luo and co-workers<sup>51</sup> reported co-crystals of PYZ and malonic acid (PYZ·MALO) and PYZ and glutaric acid (PYZ·GLT) as well as a new polymorph of PYZ and succinic acid (PYZ·SUC). Solubility measurements were conducted using *in situ* ATR-FTIR spectroscopy. With malonic acid being the most soluble of the three acids and glutaric acid being the least soluble, the solubility of the three co-crystals obtained

correlate with those of the acid co-formers.<sup>24</sup> The most soluble acid co-former resulted in a most soluble co-crystal *i.e.* the solubility order was as follows; PYZ·MALO > PYZ·GLT > PYZ·SUC (Table 2). The dissolution rate measured by the rotating disk intrinsic dissolution rate (DIDR) in pH 1.2 aqueous HCl solution on *in situ* ATR-FTIR spectroscopy follows the order PYZ·SUC < PYZ·MALO < PYZ·GLT.

Wang *et al.*<sup>52</sup> prepared four PYZ co-crystals with carboxylic acids namely; adipic acid (ADA), sebacic acid (SEB), *trans*-aconitic acid (ACA) and citric acid (CIA). PYZ·ADA and PYZ·SEB co-crystals were found to have lower solubility and IDR than PYZ while PYZ·ACA and PYZ·CIA co-crystals were found to have greater solubility and IDR than PYZ (Table 2). The greater solubility of PYZ·ACA and PYZ·CIA was attributed to the high solubility of ACA and CIA.

Sarmah *et al.*<sup>53</sup> reported five co-crystals of PYZ with 2,4 dihydroxybenzoic acid (24DHBA), 2,6 dihydroxybenzoic acid (26DHBA), 3,5 dihydroxybenzoic acid (35DHBA) and ferulic acid (FRA). The authors also report a salt of PYZ and *p*-toluene-sulfonic acid (*p*TSA). The solubility of these compounds, measured using the shake flask method in distilled water, was found to correlate with the equilibrium solubility of the co-former and they follow the order  $\text{PYZ}^+ \cdot \text{pTSA}^- > \text{PYZ} \cdot 35\text{DHBA} > \text{PYZ} > \text{PYZ} \cdot 26\text{DHBA} > \text{PYZ} \cdot 24\text{DHBA} > \text{PYZ} \cdot \text{FRA}$  (Table 2).

Abourahma *et al.*<sup>54</sup> reported two stoichiometric variations of co-crystals of PYZ and *p*-nitrobenzoic acid (*p*NBA);  $(\text{PYZ})_2 \cdot \text{pNBA}$  (2 : 1 co-crystal) and  $\text{PYZ} \cdot \text{pNBA}$  (1 : 1 co-crystal). The stability of the co-crystals was measured by suspending the compounds in methanol or acetonitrile for seven days. Analysis of the residual solid in the  $(\text{PYZ})_2 \cdot \text{pNBA}$  experiment confirmed the presence of only the 2 : 1 co-crystal. On the other hand, analysis of the residual solid in the  $\text{PYZ} \cdot \text{pNBA}$  experiment showed the presence of the 1 : 1 co-crystal as well as the 2 : 1 co-crystal indicating that the 1 : 1 co-crystal converts to the more stable 2 : 1 co-crystal. Equilibrium solubility measurements conducted on the two compounds as well as PYZ using the shake flask method follow the order  $\text{PYZ} > \text{PYZ} \cdot \text{pNBA} > (\text{PYZ})_2 \cdot \text{pNBA}$  (Table 2).

**Table 2** Equilibrium solubility values for PYZ and PYZ co-crystals in different media

Dissolution medium	Co-crystal	Solubility (mg mL <sup>-1</sup> )	Reference
pH 1.2 HCl	PYZ	22	51
	PYZ·MALO	66.5	
	PYZ·GLT	49.7	
	PYZ·SUC	37.2	
pH 1.2 HCl	PYZ	18.64	52
	PYZ·ADA	12.57	
	PYZ·SEB	12.54	
	PYZ·ACA	30.60	
	PYZ·CIA	21.05	
	PYZ	20.71	53
Water	PYZ·24DHBA	7.07	
	PYZ·26DHBA	12.18	
	PYZ·35DHBA	24.26	
	PYZ·FRA	3.33	
	$\text{PYZ}^+ \cdot \text{pTSA}^-$	39.99	
	PYZ	15.28(75)	54
Water	PYZ· <i>p</i> NBA	3.88(16)	
	$(\text{PYZ})_2 \cdot \text{pNBA}$	4.15(11)	

## 6. Conclusion

In summary, TB is a global health problem and a significant amount of research has been conducted since the discovery of *Mycobacterium tuberculosis*. The issue of drug resistance continues to be a major problem facing health systems in the treatment of TB. Even though WHO recommended the use of FDC regimens to combat resistance, they are still plagued by challenges which include chemical instability and reduced bioavailability of rifampicin. As this review shows, a significant amount of pharmaceutical co-crystal research is ongoing and is aimed at improving the stability of the active pharmaceutical ingredients in the FDCs. This review examined the multicomponent crystals of two anti-TB drugs; isoniazid and pyrazinamide. The research area itself is relatively young, with the first co-crystal of pyrazinamide having been reported less than two decades ago and a co-crystal of isoniazid first reported only eleven years ago.



An analysis of the reported structures indicated that carboxylic acids were the most commonly utilized co-formers in the preparation of pharmaceutical co-crystals of both isoniazid and pyrazinamide. For the isoniazid co-crystals, the formation of the pyridyl-N $\cdots$ HOOC heterosynthon was observed in 84% of the co-crystals while in pyrazinamide the pyrazyl-N $\cdots$ HOOC heterosynthon was observed 45% of the co-crystals. The -COOH groups in the co-crystals in which the pyrazyl-N $\cdots$ HOOC heterosynthon is not utilized are involved in carboxylic acid dimer and/or acid $\cdots$ amide interactions.

The past fifteen years have seen an increase in research efforts dedicated to preparing multicomponent crystals of pyrazinamide and isoniazid. However, structure-property studies are still very limited considering that out of the one hundred and ten (110) co-crystals of isoniazid and the forty-nine (49) co-crystals of pyrazinamide solubility and/or stability studies were reported in approximately 28% and 51% of the isoniazid and pyrazinamide co-crystals respectively. Some of the studies reviewed here found a correlation between the solubility of co-crystal and solubility of co-former while other studies found no correlation.<sup>34,37,38,51,53</sup> The nature of interactions in the crystal structure as well as the stability of the co-crystal were also shown to affect the solubility of some co-crystals.<sup>37</sup>

Co-crystallization offers the possibility of improving the physicochemical properties of isoniazid and pyrazinamide. There is still a lot that can be done given that there is a long list of compounds in the generally regarded as safe (GRAS) list which can be employed as co-formers. An increased focus on structure-property studies combined with computational studies may provide important information on how to design multicomponent crystals of isoniazid and pyrazinamide with the desired stability and solubility.

## Conflicts of interest

There are no conflicts of interests to declare.

## Acknowledgements

E. B. thanks the National Research Foundation of South Africa for financial support.

## References

- 1 I. Hershkovitz, H. D. Donoghue, D. E. Minnikin, H. May, O. Y. C. Lee, M. Feldman, E. Galili, M. Spigelman, B. M. Rothschild and G. K. Bar-Gal, *Tuberculosis*, 2015, **95**, S122–S126.
- 2 World Health Organisation, *Global Tuberculosis Report*, 2019.
- 3 World Health Organisation, *Global Tuberculosis Report*, 2018.
- 4 B. Blomberg and B. Fourie, *Drugs*, 2003, **63**, 535–553.
- 5 A. Schatz, E. Bugie and S. A. Waksman, *Proc. Soc. Exp. Biol. Med.*, 1944, **55**, 66–69.
- 6 D. Weitzman, F. E. de Wend Cayley and A. L. Wingfield, *Br. J. Tuberc. Dis. Chest*, 1950, **44**, 98–104.
- 7 The treatment of pulmonary tuberculosis with streptomycin and para-amino-salicylic acid, *Br. Med. J.* 1950, **2**, 1073–1085.
- 8 J. Lehmann, *Lancet*, 1946, **1**, 15–16.
- 9 E. Grunberg and R. J. Schnitzer, *Q. Bull. Sea View Hosp.*, 1952, **13**, 3–11.
- 10 H. Meyer and J. Mally, *Monatsh. Chem.*, 1912, **33**, 393–414.
- 11 The treatment of pulmonary tuberculosis with isoniazid, *Br. Med. J.*, 1952, **2**, 735–746.
- 12 Various combinations of isoniazid with streptomycin or with P.A.S. in the treatment of pulmonary tuberculosis, *Br. Med. J.*, 1955, **1**, 441–445.
- 13 J. G. Scadding, *Postgrad. Med. J.*, 1951, **27**, 549–558.
- 14 J. F. Murray, D. E. Schraufnagel and P. C. Hopewell, *Ann. Am. Thorac. Soc.*, 2015, **12**, 1749–1759.
- 15 Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis, *Lancet*, 1974, **304**, 237–240.
- 16 Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis: the results up to 30 months, *Am. Rev. Respir. Dis.*, 1979, **119**, 579–589.
- 17 R. L. Yeagen, W. G. C. Munice and F. I. Dessai, *Am. Rev. Tuberc.*, 1952, **65**, 523–546.
- 18 N. Maggi, C. R. Pasqualucci, R. Ballotta and P. Sensi, *Chemotherapy*, 1966, **11**, 285–292.
- 19 J. P. Thomas, C. O. Baughn, R. G. Wilkinson and R. G. Shepherd, *Am. Rev. Respir. Dis.*, 1961, **83**, 891–893.
- 20 S. Singh, H. Bhutani and T. T. Mariappan, *Indian J. Tuberc.*, 2006, **53**, 201–205.
- 21 R. Sankar, N. Sharda and S. Singh, *Drug Dev. Ind. Pharm.*, 2003, **29**, 733–738.
- 22 S. Singh, T. T. Mariappan, N. Sharda and B. Singh, *Pharm. Pharmacol. Commun.*, 2000, **6**, 491–494.
- 23 G. R. Desiraju, *Angew. Chem., Int. Ed.*, 2007, **46**, 8342–8356.
- 24 D. J. Good and R. H. Nair, *Cryst. Growth Des.*, 2009, **9**, 2252–2264.
- 25 N. Qiao, M. Li, W. Schlindwein, N. Malek, A. Davies and G. Trappitt, *Int. J. Pharm.*, 2011, **419**, 1–11.
- 26 L. Roy, M. P. Lipert, N. Rodríguez-Hornedo, W. Jones, R. Thakuria and A. Delori, *Int. J. Pharm.*, 2012, **453**, 101–125.
- 27 M. Rodrigues, B. Baptista, J. A. Lopes and M. C. Sarraguça, *Int. J. Pharm.*, 2018, **547**, 404–420.
- 28 D. Braga, S. L. Giffreda, F. Grepioni, M. R. Chierotti, R. Gobetto, G. Palladino and M. Polito, *CrystEngComm*, 2007, **9**, 879–881.
- 29 C. C. Robertson, J. S. Wright, E. J. Carrington, R. N. Perutz, C. A. Hunter and L. Brammer, *Chem. Sci.*, 2017, **8**, 5392–5398.
- 30 E. Pindelska, A. Sokal and W. Kolodziejski, *Adv. Drug Delivery Rev.*, 2017, **117**, 111–146.
- 31 C. R. Groom, I. J. Bruno, M. P. Lightfoot and S. C. Ward, *Acta Crystallogr., Sect. B: Struct. Sci., Cryst. Eng. Mater.*, 2016, **72**, 171–179.
- 32 C. B. Aakeröy, J. Desper and B. A. Helfrich, *CrystEngComm*, 2004, **6**, 19–24.
- 33 L. F. Diniz, M. S. Souza, P. S. Carvalho, C. C. Correa and J. Ellena, *J. Mol. Struct.*, 2018, **1171**, 223–232.
- 34 S. Aitipamula, A. B. H. Wong, P. S. Chow and R. B. H. Tan, *CrystEngComm*, 2013, **15**, 5877–5887.



- 35 S. Cherukuvada and A. Nangia, *CrystEngComm*, 2012, **14**, 2579–2588.
- 36 A. Lemmerer, *CrystEngComm*, 2012, **14**, 2465–2478.
- 37 I. Sarcevic, L. Orola, M. V. Veidis, A. Podjava and S. Belyakov, *Cryst. Growth Des.*, 2013, **13**, 1082–1090.
- 38 B. Swapna, D. Maddileti and A. Nangia, *Cryst. Growth Des.*, 2014, **14**, 5991–6005.
- 39 J. Rosa, T. C. Machado, A. K. Da Silva, G. Kuminek, A. J. Bortolluzzi, T. Caon and S. G. Cardoso, *Cryst. Growth Des.*, 2019, **19**, 5029–5036.
- 40 N. Ravikumar, G. Gaddamanugu and K. Anand Solomon, *J. Mol. Struct.*, 2013, **1033**, 272–279.
- 41 S. M. A. Mashhadi, U. Yunus, M. H. Bhatti and M. N. Tahir, *J. Mol. Struct.*, 2014, **1076**, 446–452.
- 42 S. M. A. Mashhadi, U. Yunus, M. H. Bhatti, I. Ahmed and M. N. Tahir, *J. Mol. Struct.*, 2016, **1117**, 17–21.
- 43 P. Grobelny, A. Mukherjee and G. R. Desiraju, *CrystEngComm*, 2011, **13**, 4358–4364.
- 44 P. Sanphui, N. J. Babu and A. Nangia, *Cryst. Growth Des.*, 2013, **13**, 2208–2219.
- 45 M. K. Bommaka, M. K. Chaitanya Mannava, K. Suresh, A. Gunnam and A. Nangia, *Cryst. Growth Des.*, 2018, **18**, 6061–6069.
- 46 F. Liu, L. Y. Wang, Y. T. Li, Z. Y. Wu and C. W. Yan, *Cryst. Growth Des.*, 2018, **18**, 3729–3733.
- 47 J. R. Wang, C. Ye and X. Mei, *CrystEngComm*, 2014, **16**, 6996–7003.
- 48 S. P. Gopi, M. Banik and G. R. Desiraju, *Cryst. Growth Des.*, 2017, **17**, 308–316.
- 49 M. S. Souza, L. F. Diniz, L. Vogt, P. S. Carvalho, R. F. D'Vries and J. Ellena, *Cryst. Growth Des.*, 2018, **18**, 5202–5209.
- 50 F. Liu, Y. Song, Y. N. Liu, Y. T. Li, Z. Y. Wu and C. W. Yan, *Cryst. Growth Des.*, 2018, **18**, 1283–1286.
- 51 Y. H. Luo and B. W. Sun, *Cryst. Growth Des.*, 2013, **13**, 2098–2106.
- 52 J. R. Wang, C. Ye, B. Zhu, C. Zhou and X. Mei, *CrystEngComm*, 2015, **17**, 747–752.
- 53 K. K. Sarmah, T. Rajbongshi, S. Bhowmick and R. Thakuria, *Acta Crystallogr., Sect. B: Struct. Sci., Cryst. Eng. Mater.*, 2017, **73**, 1007–1016.
- 54 H. Abourahma, D. D. Shah, J. Melendez, E. J. Johnson and K. T. Holman, *Cryst. Growth Des.*, 2015, **15**, 3101–3104.

